Alto Neuroscience, Inc. announced today that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375. This patent covers method claims pertaining to the treatment of major depressive disorder (MDD) in patients who have shown an inadequate response to an antidepressant.
The granted patent specifically includes treatment with ALTO-300 as an adjunctive therapy, coupled with patient selection using specific electroencephalogram (EEG) measures. This underscores Alto's novel approach to patient selection in neuropsychiatric treatment using objective biomarkers.
The patent is expected to cover the use of ALTO-300 in the EEG-defined patient population until 2044, not accounting for any potential patent term extensions. This intellectual property protection strengthens Alto's position in developing targeted treatments for MDD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.